Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/5392
Title: | Phase 1 trial of intrapleural LTI-01; single chain urokinase in complicated parapneumonic effusions or empyema | Authors: | Beckert, Lutz Brockway, Ben Simpson , Graham Southcott, Anne Marie Lee, Y C Gary Rahman, Najib Light, Richard W Shoemaker, Steven Gillies, John Komissarov, Andrey A Florova, Galina Ochran, Timothy Bradley, William Ndetan, Harrison Singh, Karan P Sarva, Krishna Idell, Steven |
Issue Date: | 2019 | Publisher: | American Society for Clinical Investigation | Source: | Beckert L, Brockway B, Simpson G, Southcott AM, Lee YCG, Rahman N, Light RW, Shoemaker S, Gillies J, Komissarov AA, Florova G, Ochran T, Bradley W, Ndetan H, Singh KP, Sarva K, Idell S. Phase 1 trial of intrapleural LTI-01; single chain urokinase in complicated parapneumonic effusions or empyema. JCI Insight. 2019 Apr 18;5(10):e127470. doi: 10.1172/jci.insight.127470. PMID: 30998508; PMCID: PMC6542611. | Journal: | JCI insight | Abstract: | Current dosing of intrapleural fibrinolytic therapy (IPFT) in adults with complicated parapneumonic effusion (CPE) / empyema is empiric, as dose-escalation trials have not previously been conducted. We hypothesized that LTI-01 (scuPA), which is relatively resistant to PA inhibitor-1 (PAI-1), would be well-tolerated. This was an open-label, dose-escalation trial of LTI-01 IPFT at 50,000-800,000 IU daily for up to 3 days in adults with loculated CPE/empyema and failed pleural drainage. The primary objective was to evaluate safety and tolerability, and secondary objectives included assessments of processing and bioactivity of scuPA in blood and pleural fluid (PF), and early efficacy. LTI-01 was well tolerated with no bleeding, treatment-emergent adverse events or surgical referrals (n=14 subjects). uPA antigen increased in PFs at 3 hours after LTI-01 (p<0.01) but not in plasma. PF saturated active PAI-1, generated PAI-1-resistant bioactive complexes, increased PA and fibrinolytic activities and D-dimers. There was no systemic fibrinogenolysis, nor increments in plasma D-dimer. Decreased pleural opacities occurred in all but one subject. Both subjects receiving 800,000 IU required two doses to relieve pleural sepsis, with two other subjects similarly responding at lower doses. LTI-01 IPFT was well-tolerated at these doses with no safety concerns. Bioactivity of LTI-01 IPFT was confirmed, limited to PFs where its processing simulated that previously reported in preclinical studies. Preliminary efficacy signals including reduction of pleural opacity were observed. | Description: | Cairns & Hinterland Hospital and Health Service (CHHHS) affiliated author: Graham Simpson | DOI: | 10.1172/jci.insight.127470 | Keywords: | Bacterial infections;Clinical Trials;Fibrosis | Type: | Article |
Appears in Sites: | Cairns & Hinterland HHS Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.